Key enhancements include
Expanded the ocular (OCAT) , oral cavity (OCCAT) , and dermal (TCAT) models by adding new formulation and PK/PD mechanisms to better capture local and systemic exposure levels in animals and humans
Extended the ACAT model to enhance the evaluation of formulation approaches for local gastrointestinal (GI) disease states
Improved Biologics Module features to mimic study designs and refine dose optimization simulations for clinical trial success
Upgraded with ADMET Predictor version 11 models, enhancing our First in Human Simulator
'Our software updates reflect the needs our customers communicate to us, and GastroPlus 9.9 is no exception,' said
'For many years, we have worked on collaborative projects with the FDA and other regulatory agencies to improve the technology available to the pharmaceutical industry and increase the safety of animal and human trials,' said Dr.
GastroPlus 9.9 is available now for licensing and download .
About
Serving clients worldwide for more than 25 years,
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2022 ESG update .
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like 'believe,' 'expect' and 'anticipate' mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the
Contact:
Tel: 661-723-7723
Email: renee.bouche@simulations-plus.com
Tel: 310-622-8251
Email: slp@finprofiles.com
(C) 2024 Electronic News Publishing, source